Eli Lilly LLY announced that the phase IV CHALLENGE-MIG study, evaluating the efficacy and safety of its migraine drug Emgality against Pfizer‘s PFE Nurtec ODT, failed to meet primary endpoint of ...

(Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal ...

A Massachusetts federal judge has sided with Eli Lilly in a patent spat, overturning a $176.5 million jury verdict from November of last year. The verdict had been awarded to Teva in a patent ...

Two months after a federal judge overturned a $176 million jury verdict against Eli Lilly and Co in a patent infringement lawsuit, the dispute seems to be winding down. Indianapolis-based Lilly and ...

(Reuters) -Eli Lilly said on Friday its migraine prevention drug failed to show superiority to a rival from Pfizer Inc in a post-approval study. The three-month study, which involved 580 patients, was ...

A federal judge has overturned a $176.5 million jury verdict against Eli Lilly and Co., finding that the Indianapolis-based drugmaker did not infringe on the patents of a competitor in developing a ...

INDIANAPOLIS, May 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present 19 scientific abstracts for Emgality ® (galcanezumab-gnlm) and lasmiditan at the 71 st ...

Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

Eli Lilly And Co (NYSE:LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet). Emgality did not meet ...

Teva Pharmaceuticals International GmbH alleged that Eli Lilly and Co. infringed on three of its patents and the use of anti-CGRP antagonist antibodies to treat migraines. Teva has an antibody product ...

Nov 9 (Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston ...